A Review of Therapies for <i>Clostridioides difficile</i> Infection

A Review of Therapies for <i>Clostridioides difficile</i> Infection

<i>Clostridioides difficile</i> is an urgent public health threat that affects approximately half a million patients annually in the United States. Despite concerted efforts aimed at the prevention of <i>Clostridioides difficile</i> infection (CDI), it remains a leading cause...

Bibliografski detalji
Glavni autori:	Faiza Morado, Neha Nanda
Format:	Članak
Jezik:	English
Izdano:	MDPI AG 2024-12-01
Serija:	Antibiotics
Teme:	<i>C. difficile</i> infection recurrent <i>C. difficile</i> infection metronidazole vacomycin fidaxomicin fecal microbiota transplantation
Online pristup:	https://www.mdpi.com/2079-6382/14/1/17

Slični predmeti

Controversies in the Prevention and Treatment of <i>Clostridioides difficile</i> Infection in Adults: A Narrative Review
od: Taryn B. Bainum, i dr.
Izdano: (2023-02-01)

Updated Management Guidelines for <i>Clostridioides difficile</i> in Paediatrics
od: Margherita Gnocchi, i dr.
Izdano: (2020-04-01)

<i>Clostridioides difficile</i> Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis
od: Alice Annalisa Medaglia, i dr.
Izdano: (2023-04-01)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating <i>Clostridioides difficile</i> Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
od: Nobuaki Mori, i dr.
Izdano: (2023-08-01)

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study
od: Marcos Hernando-Gozalo, i dr.
Izdano: (2024-05-01)

Application of Microbiome Management in Therapy for <i>Clostridioides difficile</i> Infections: From Fecal Microbiota Transplantation to Probiotics to Microbiota-Preserving Antimicrobial Agents
od: Chun-Wei Chiu, i dr.
Izdano: (2021-05-01)

The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
od: Ronald G. Hall, i dr.
Izdano: (2022-02-01)

<i>Clostridioides difficile</i> infection in hospital and community settings: summary document of a multidisciplinary group
od: Anna Danise, i dr.
Izdano: (2024-02-01)

Microbiota in <i>Clostridioides difficile</i>-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections
od: Alessandra Gazzola, i dr.
Izdano: (2020-09-01)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
od: Teena Chopra, i dr.
Izdano: (2023-01-01)

Efficacy and Safety of Fecal Microbiota Transplantation in Treatment of <i>Clostridioides difficile</i> Infection among Pediatric Patients: A Systematic Review and Meta-Analysis
od: Kyaw Min Tun, i dr.
Izdano: (2022-12-01)

Insights into the Role of Human Gut Microbiota in <i>Clostridioides difficile</i> Infection
od: Melina Kachrimanidou, i dr.
Izdano: (2020-01-01)

Iron Effects on <i>Clostridioides difficile</i> Toxin Production and Antimicrobial Susceptibilities
od: Jason Yamaki, i dr.
Izdano: (2022-04-01)

Factors Related to Outcomes of Fecal Microbiota Transplantation in Patients with Clostridioides difficile Infection
od: Hyuk Yoon, i dr.
Izdano: (2021-01-01)

Does Fecal Microbiota Transplant Have a Role in Treating Recurrent Clostridioides difficile Infection in Rural Hospitals?
od: Krishna Vedala, i dr.
Izdano: (2021-06-01)

Does Fidaxomicin reduce Cure and Recurrence rates compared to Vancomycin in Clostridium Difficile Infection patients?: A Systematic Review and Meta-analysis
od: Hiral N Golakiya, i dr.
Izdano: (2022-06-01)

The Efficacy of Fecal Microbiota Transplantation in Mouse Models Infected with <i>Clostridioides difficile</i> from the Perspective of Metabolic Profiling: A Systematic Review
od: Anna Voziki, i dr.
Izdano: (2024-12-01)

Clostridioides difficile infection: a comprehensive review for primary providers
od: Cortés Pedro, i dr.
Izdano: (2021-09-01)

Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and <i>Clostridioides difficile</i>
od: Adrian Boicean, i dr.
Izdano: (2022-12-01)

Host Immune Responses to <i>Clostridioides difficile</i> Infection and Potential Novel Therapeutic Approaches
od: Md Zahidul Alam, i dr.
Izdano: (2023-11-01)

Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection — An observational cohort study
od: Sylvia Polivkova, i dr.
Izdano: (2021-02-01)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
od: Laura Whitney, i dr.
Izdano: (2023-01-01)

<i>Clostridioides difficile</i> Infection: Diagnosis and Treatment Challenges
od: John E. Markantonis, i dr.
Izdano: (2024-01-01)

Metronidazole for Treatment of <i>Clostridioides difficile</i> Infections in Brazil: A Single-Center Experience and Risk Factors for Mortality
od: Joana Darc Freitas Alves, i dr.
Izdano: (2022-08-01)

The Bactericidal Activity and Spore Inhibition Effect of Manuka Honey against <i>Clostridioides Difficile</i>
od: Lillian Yu, i dr.
Izdano: (2020-10-01)

Gut Microbiota Composition Associated with <i>Clostridioides difficile</i> Colonization and Infection
od: Elisa Martinez, i dr.
Izdano: (2022-07-01)

Is Three Company or a Crowd? Comparing and Contrasting U.S. and European <i>Clostridioides</i><i>difficile</i> Clinical Practice Guidelines
od: Jordan Jones, i dr.
Izdano: (2022-09-01)

Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent <named-content content-type="genus-species">Clostridioides difficile</named-content> Infection
od: Danielle Barrios Steed, i dr.
Izdano: (2020-10-01)

In Silico Analysis of Changes in Predicted Metabolic Capabilities of Intestinal Microbiota after Fecal Microbial Transplantation for Treatment of Recurrent <i>Clostridioides difficile</i> Infection
od: Monica Dahiya, i dr.
Izdano: (2023-04-01)

Effect of Restriction of Fluoroquinolone Antibiotics on <i>Clostridioides difficile</i> Infections in the University Hospital Hradec Králové
od: Kristýna Vaverková, i dr.
Izdano: (2021-05-01)

Strong Antimicrobial Effects of Xanthohumol and Beta-Acids from Hops against <i>Clostridioides difficile</i> Infection In Vivo
od: Radek Sleha, i dr.
Izdano: (2021-04-01)

Occurrence of <i>Blastocystis</i> in Patients with <i>Clostridioides difficile</i> Infection
od: Laura Vega, i dr.
Izdano: (2020-04-01)

Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications
od: Nityanand Jain, i dr.
Izdano: (2023-12-01)

Comparative Efficacy of Fecal Microbiota Transplantation in Treating Refractory or Recurrent <i>Clostridioides difficile</i> Infection among Patients with and without Inflammatory Bowel Disease: A Retrospective Cohort Study
od: Jing-Han Chen, i dr.
Izdano: (2024-06-01)

Biofilm Formation of <i>Clostridioides difficile</i>, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI
od: Leon M. T. Dicks
Izdano: (2023-08-01)

Investigation of Intestinal Microbiota and Fecal Calprotectin in Non-Toxigenic and Toxigenic <i>Clostridioides difficile</i> Colonization and Infection
od: Sung-Hee Han, i dr.
Izdano: (2020-06-01)

High Prevalence of <i>Clostridioides difficile</i> Ribotype 176 in the University Hospital in Kosice
od: Katarina Curova, i dr.
Izdano: (2023-03-01)

Assessing the Feasibility of Employing a Combination of a Bacteriophage-Derived Endolysin and Spore Germinants to Treat Relapsing <i>Clostridioides difficile</i> Infection
od: Khalid Alyahya, i dr.
Izdano: (2023-06-01)

Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value
od: D'Ostroph AR, i dr.
Izdano: (2017-10-01)

Microbiome-Related and Infection Control Approaches to Primary and Secondary Prevention of <i>Clostridioides difficile</i> Infections
od: Lynne V. McFarland, i dr.
Izdano: (2023-06-01)